• Our products

  • 1

General Medicine

VERIFI®, is a non-invasive prenatal test (NIPT), offering early genetic screening for chromosomal abnormalities using just one tube of blood—as early as 10 weeks into a patient’s pregnancy. Verifi analyzes cell free fetal and maternal DNA from a blood sample to screen for common chromosome conditions including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). Verifi poses minimal risk to the mother or baby with high detection rates and low false positives.

PYLERA® (bismuth subcitrate potassium, metronidazole, tetracycline HCl) in combination with omeprazole, is a 3-in-1 capsule for  the eradication treatment of Helicobacter pylori. The eradication of Helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence as well as reduce the risk of gastric cancer.

GLICONORM™, Glibenclamide + Metformin hydrochloride, is a second line therapy to treat non-insulin dependent diabetes mellitus. This fixed dose in one tablet provides convenience for patients and helps increase patient compliance.

DIBASE, Cholecalciferol (vitamin D3), is used in the treatment of hypoparathyroidism, vitamin D resistant rickets, and low vitamin D levels.

AFIRMA® Thyroid FNA Analysis is a comprehensive solution that combines the advantages of specialized cytopathology with the power of genomics. Afirma GEC analyzes the expression level of 142 different genes. Together, these genes demonstrate a recognizable pattern of expression in benign thyroid nodules. Afirma can help doctors identify benign nodules when cytopathology is indeterminate, thereby reducing the number of unnecessary thyroid surgeries. And, if the patient needs surgery, Afirma can also provide valuable additive information that may help guide decisions on the appropriate surgery – all from one FNA.

*for full prescribing information please refer to your locally approved label*


  • 1